{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T10:18:56Z","timestamp":1772619536418,"version":"3.50.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T00:00:00Z","timestamp":1754524800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T00:00:00Z","timestamp":1754524800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100004000","name":"Guangzhou Municipal Science and Technology Program key projects","doi-asserted-by":"publisher","award":["2023A03J0814"],"award-info":[{"award-number":["2023A03J0814"]}],"id":[{"id":"10.13039\/501100004000","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virchows Arch"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s00428-025-04208-0","type":"journal-article","created":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T05:27:55Z","timestamp":1754544475000},"page":"1035-1045","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Small bowel metastatic SWI\/SNF-deficient undifferentiated carcinoma may be predictive of lung primary\u2014a rare presentation with novel SMARCA2 mutation findings in a study of three cases"],"prefix":"10.1007","volume":"487","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0097-5479","authenticated-orcid":false,"given":"Chi Sing","family":"Ng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jilong","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chi Hang","family":"Kan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristopher T.","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,7]]},"reference":[{"key":"4208_CR1","first-page":"427","volume":"8","author":"K Washington","year":"1995","unstructured":"Washington K, McDonagh D (1995) Secondary tumors of the gastrointestinal tract: surgical pathology findings and comparison with autopsy survey. Mod Pathol 8:427\u2013433","journal-title":"Mod Pathol"},{"key":"4208_CR2","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.lungcan.2006.08.007","volume":"54","author":"C Yang","year":"2006","unstructured":"Yang C, Hwang J, Kang W, Chong I, Wang T, Sheu C et al (2006) Gastrointestinal metastasis of primary lung carcinoma: clinical presentations and outcome. Lung Cancer 54:319\u2013323. https:\/\/doi.org\/10.1016\/j.lungcan.2006.08.007","journal-title":"Lung Cancer"},{"key":"4208_CR3","doi-asserted-by":"publisher","first-page":"9766","DOI":"10.3892\/0l.2018.8575","volume":"15","author":"Y Hu","year":"2018","unstructured":"Hu Y, Feit N, Huang Y, Xu W, Zheng S, Li X (2018) Gastrointestinal metastasis of primary lung cancer: an analysis of 366 cases. Oncol Lett 15:9766\u20139776. https:\/\/doi.org\/10.3892\/0l.2018.8575","journal-title":"Oncol Lett"},{"key":"4208_CR4","doi-asserted-by":"publisher","first-page":"157","DOI":"10.10007\/s00428-021-03032-6","volume":"479","author":"A Agaimy","year":"2021","unstructured":"Agaimy A, Daum O, Michal M, Schmidt MW, Stoehr R, Hartmann A et al (2021) Undifferentiated large cell\/rhabdoid carcinoma presenting in the intestine of patients with concurrent or recent non-small cell lung cancer (NSCLC): clinicopathologic analysis of 14 cases indicates an unusual pattern of dedifferentiated metastases. Virchow Archiv 479:157\u2013167. https:\/\/doi.org\/10.10007\/s00428-021-03032-6","journal-title":"Virchow Archiv"},{"key":"4208_CR5","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1111\/cas.12065","volume":"104","author":"D Matubara","year":"2013","unstructured":"Matubara D, Kishaba Y, Ishikawa S, Sakatani T, Oguni S, Tamura T et al (2013) Lung cancer with loss of BRG1\/BRM shows epithelial mesenchymal transition phenotypes and distinct histologic and genetic features. Cancer Sci 104:266\u2013273. https:\/\/doi.org\/10.1111\/cas.12065","journal-title":"Cancer Sci"},{"key":"4208_CR6","doi-asserted-by":"publisher","unstructured":"Daggo-Jack I, Schrock AB, Kem M, Jessop N, Lee J, Ali SM et al (2020) Clinicopathologic characteristics of BRG1-deficient NSCLC. J Thorac Oncol 15:766\u2013776.\u00a0https:\/\/doi.org\/10.1016\/jtho.22020.01.002.","DOI":"10.1016\/jtho.22020.01.002"},{"key":"4208_CR7","doi-asserted-by":"publisher","unstructured":"Ng CS, Qin J (2025) Switch\/sucrose nonfermentable deficient tumors \u2013 morphology, immunophenotype, genetics, epigenetics, nosology and therapy. Lab Invest 105:102185. https:\/\/doi.org\/10.1016\/j.labinv.2024","DOI":"10.1016\/j.labinv.2024"},{"key":"4208_CR8","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1265\/ehpm.21.00254","volume":"27","author":"S Sun","year":"2022","unstructured":"Sun S, Li Q, Zhang Z, Xiong S, Zhang Y, Liu Q et al (2022) SMARCA2 deficiency in NSCLC: a clinicopathologic and immunohistochemical analysis of a large series from a single institution. Env Health Prev Med 27:3. https:\/\/doi.org\/10.1265\/ehpm.21.00254","journal-title":"Env Health Prev Med"},{"key":"4208_CR9","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s00418-004-0693-x","volume":"122","author":"S Shi","year":"2004","unstructured":"Shi S, Datar R, Liu C, Wu L, Zhang Z, Cote RJ et al (2004) DNA extraction from archival formalin-fixed, paraffin-embedded tissues: heat-induced retrieval in alkaline solution. Histochem Cell Biol 122:211\u2013218. https:\/\/doi.org\/10.1007\/s00418-004-0693-x","journal-title":"Histochem Cell Biol"},{"key":"4208_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/gigascience\/gix024","volume":"6","author":"J Huang","year":"2017","unstructured":"Huang J, Liang Y, Xuan Y, Geng C, Li Y, Lu H et al (2017) A reference human genome dataset of the BGISEQ-500 sequencer. Gigascience 6:1\u20139. https:\/\/doi.org\/10.1093\/gigascience\/gix024","journal-title":"Gigascience"},{"key":"4208_CR11","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s00428-017-2148-5","volume":"471","author":"A Agaimy","year":"2017","unstructured":"Agaimy A, Fuchs F, Moskalev EA, Sirbu H, Hartman A, Haller F (2017) SMARCA4-deficient pulmonary adenocarcinoma: clinicopathological, immunohistochemical, and molecular characteristics of a novel aggressive neoplasm with a consistent TTF1neg\/CK7neg\/HepPar-1pos immunophenotype. Virchows Arch 471:599\u2013609. https:\/\/doi.org\/10.1007\/s00428-017-2148-5","journal-title":"Virchows Arch"},{"key":"4208_CR12","doi-asserted-by":"publisher","first-page":"5701","DOI":"10.1158\/1078-0432.CCR-20-1825","volume":"26","author":"AJ Schoenfeld","year":"2020","unstructured":"Schoenfeld AJ, Bandlamudi C, Lavery JA, Monteclavo J, Namakydoust A, Rivi H et al (2020) The genomic landscape of SMARCA4 alterations and associations with outcomes in patients with lung cancers. Clin Cancer Res 26:5701\u20135708. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-1825","journal-title":"Clin Cancer Res"},{"key":"4208_CR13","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/nrc3068","volume":"11","author":"BG Wilson","year":"2011","unstructured":"Wilson BG, Roberts CW (2011) SWI\/SNF nucleosome remodelers and cancer. Nat Rev Cancer 11:481\u2013492. https:\/\/doi.org\/10.1038\/nrc3068","journal-title":"Nat Rev Cancer"},{"key":"4208_CR14","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1038\/ng.2628","volume":"45","author":"C Kadoch","year":"2013","unstructured":"Kadoch C, Hargreaves DC, Hodges C, Elias L, Ho L, Ranish J et al (2013) Proteomic and bioinformatics analysis of mammalian SWI\/SNF complexes identifies extensive roles in human malignancy. Nat Genet 45:592\u2013601. https:\/\/doi.org\/10.1038\/ng.2628","journal-title":"Nat Genet"},{"key":"4208_CR15","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/s41388-021-01781-x","volume":"77","author":"D Wankhede","year":"2024","unstructured":"Wankhede D, Grover S, Hofman P (2024) SMARCA4 alterations in non-small cell lung cancer: a systemic review and meta-analysis. J Clin Pathol 77:457\u2013463. https:\/\/doi.org\/10.1038\/s41388-021-01781-x","journal-title":"J Clin Pathol"},{"key":"4208_CR16","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1093\/hmg\/ddu554","volume":"24","author":"IF Coira","year":"2015","unstructured":"Coira IF, Rufino-Palomares EE, Romero OA, Peinado P, Metheetrairut C, Boyero-Corral L et al (2015) Expression inactivation of SMARCA4 by microRNAs in lung tumors. Hum Mol Genet 24:1400\u20131409. https:\/\/doi.org\/10.1093\/hmg\/ddu554","journal-title":"Hum Mol Genet"},{"key":"4208_CR17","doi-asserted-by":"publisher","first-page":"372","DOI":"10.3389\/fonc.2014.00372","volume":"4","author":"S Marquez","year":"2015","unstructured":"Marquez S, Kenneth T, Reisman D (2015) Beyond mutations: additional mechanisms and implications of SWI\/SNF complex inactivation. Front Oncol 4:372. https:\/\/doi.org\/10.3389\/fonc.2014.00372","journal-title":"Front Oncol"},{"key":"4208_CR18","doi-asserted-by":"publisher","first-page":"7058","DOI":"10.1038\/sj.onc.1210514","volume":"26","author":"S Glaros","year":"2007","unstructured":"Glaros S, Cirrincione GM, Muchardt C, Kleer CG, Michael CW, Reisman D (2007) The reversible epigenetic silencing of BRM: implications for clinical targeted therapy. Oncogene 26:7058\u20137066. https:\/\/doi.org\/10.1038\/sj.onc.1210514","journal-title":"Oncogene"},{"key":"4208_CR19","doi-asserted-by":"publisher","first-page":"6505","DOI":"10.1093\/emboj\/cdg621","volume":"22","author":"B Bourachot","year":"2003","unstructured":"Bourachot B, Yaniv M, Muchart C (2003) Growth inhibition by mammalian SWI\/SNF subunit BRM is regulated by acetylation. EMBO 22:6505\u20136515. https:\/\/doi.org\/10.1093\/emboj\/cdg621","journal-title":"EMBO"},{"key":"4208_CR20","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.gene.2018.11.032","volume":"687","author":"J Wu","year":"2019","unstructured":"Wu J, He K, Zhang Y, Song J, Shi Z, Chen W et al (2019) Inactivation of SMARCA2 by promoter hypermethylation drives lung cancer development. Gene 687:193\u2013199. https:\/\/doi.org\/10.1016\/j.gene.2018.11.032","journal-title":"Gene"},{"key":"4208_CR21","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/jtho2019.10.023","volume":"15","author":"N Rhekhtman","year":"2020","unstructured":"Rhekhtman N, Monteclavo J, Chang JC, Alex D, Ptashkin RN, Sauter JL et al (2020) SMARCA4-deficient thoracic sarcomatoid tumors represent primarily smoking-related carcinomas rather than primarily thoracic sarcomas. J Thorac Oncol 15:231\u2013247. https:\/\/doi.org\/10.1016\/jtho2019.10.023","journal-title":"J Thorac Oncol"},{"key":"4208_CR22","doi-asserted-by":"publisher","first-page":"14171","DOI":"10.1002\/cam4.6083","volume":"12","author":"X Liang","year":"2023","unstructured":"Liang X, Gao X, Wang F, Li S, Zhou Y, Guo P et al (2023) Clinical characteristics and prognostic analysis of SMARCA4-deficient non-small cell lung cancer. Cancer Med 12:14171\u201314182. https:\/\/doi.org\/10.1002\/cam4.6083","journal-title":"Cancer Med"},{"key":"4208_CR23","doi-asserted-by":"publisher","first-page":"e255","DOI":"10.1016\/j.jtho.2018.07.099","volume":"13","author":"N Karachaliou","year":"2018","unstructured":"Karachaliou N, Bracht JWP, Rosell R (2018) ARID1A gene driver mutations in lung adenocarcinomas. J Thorac Oncol 13:e255\u2013e257. https:\/\/doi.org\/10.1016\/j.jtho.2018.07.099","journal-title":"J Thorac Oncol"},{"key":"4208_CR24","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s10020-020-00208-9","volume":"26","author":"D Sun","year":"2020","unstructured":"Sun D, Tian L, Zhu Y, Wo Y, Liu Q, Li H et al (2020) Subunits of ARID1 serve as novel biomarkers for sensitivity to immune checkpoint inhibitors and prognosis of advanced non-small cell lung cancer. Mol Med 26:78. https:\/\/doi.org\/10.1186\/s10020-020-00208-9","journal-title":"Mol Med"},{"key":"4208_CR25","doi-asserted-by":"crossref","unstructured":"Zhu G, Shi R, Li Y et al (2021) ARID1A, ARID1B and ARID2 mutations serve as potential biomarkers for immune checkpoint blockade in patients with non-small cell lung cancer. Front Immunol 12:670040. https:\/\/doi.org\/10.103389\/fimmu.2021.670040.eCollection2021","DOI":"10.3389\/fimmu.2021.670040"},{"key":"4208_CR26","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.mol.med.2023.04.005","volume":"29","author":"F Jin","year":"2023","unstructured":"Jin F, Yang Z, Shao J, Tao J, ReiBfelder C, Loges S et al (2023) ARID1A mutations in lung cancer: biology, prognostic role and therapeutic implications. Mol Med 29:646\u2013658. https:\/\/doi.org\/10.1016\/j.mol.med.2023.04.005","journal-title":"Mol Med"},{"key":"4208_CR27","doi-asserted-by":"publisher","unstructured":"Zhou H, Liu J, Zhang Y, Huang Y, Shen J, Yang Y et al (2020)\u00a0PBRM1 mutation and preliminary response to immune checkpoint blockade treatment in non-small cell lung cancer. npj Precis Onc 4:6.https:\/\/doi.org\/10.1038\/s41698-020-0112-3","DOI":"10.1038\/s41698-020-0112-3"},{"key":"4208_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1126\/science.adg7492","volume":"381","author":"J Cheng","year":"2023","unstructured":"Cheng J, Novati G, Pan J, Bycroft C, Zemgulyte A, Applebaum T et al (2023) Accurate proteome-wide missense variant effect prediction with AlphaMissense. Science 381:1\u201311. https:\/\/doi.org\/10.1126\/science.adg7492","journal-title":"Science"},{"key":"4208_CR29","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1111\/1759-7714.12613","volume":"9","author":"X Du","year":"2018","unstructured":"Du X, Shao Y, Qin H, Tai Y, Gao H et al (2018) ALK rearrangement in non-small cell lung cancer (NSCLC). Thorac Cancer 9:423\u2013430. https:\/\/doi.org\/10.1111\/1759-7714.12613","journal-title":"Thorac Cancer"},{"key":"4208_CR30","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1136\/esmoopen-2020-000919","volume":"5","author":"A Passaro","year":"2020","unstructured":"Passaro A, Malapelle U, Del Re M, Attili I, Russo A, Guerini-Rocco E et al (2020) Understanding EGFR heterogeneity in lung cancer. ESMO Open 5:5. https:\/\/doi.org\/10.1136\/esmoopen-2020-000919","journal-title":"ESMO Open"},{"key":"4208_CR31","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/nrc3580","volume":"13","author":"B Hallerg","year":"2013","unstructured":"Hallerg B, Palmer RH (2013) Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology. Nat Rev Cancer 13:685\u2013700. https:\/\/doi.org\/10.1038\/nrc3580","journal-title":"Nat Rev Cancer"},{"key":"4208_CR32","doi-asserted-by":"publisher","first-page":"641","DOI":"10.3390\/curroncol29020057","volume":"29","author":"S Gendarine","year":"2022","unstructured":"Gendarine S, Bylicki O, Chonaid C, Guisier F (2022) ROS1-fusion in non-small \u2013cell lung cancer: evidence to date. Curr Oncol 29:641\u2013658. https:\/\/doi.org\/10.3390\/curroncol29020057","journal-title":"Curr Oncol"},{"key":"4208_CR33","doi-asserted-by":"publisher","first-page":"709","DOI":"10.3390\/jcm12020709","volume":"12","author":"Y Yang","year":"2023","unstructured":"Yang Y, Zhang H, Huang S, Chu Q (2023) KRAS mutations in solid tumors: characteristics, current therapeutic strategy, and potential treatment exploration. J Clin Med 12:709. https:\/\/doi.org\/10.3390\/jcm12020709","journal-title":"J Clin Med"},{"key":"4208_CR34","doi-asserted-by":"publisher","first-page":"192","DOI":"10.3892\/ol.2023.13778","volume":"25","author":"K Matsunaga","year":"2023","unstructured":"Matsunaga K, Sasaki K, Hata K, Nozawa H, Kawai K, Murono K et al (2023) Clinical significance of the KRAS G13D mutation in anastomotic recurrence of colorectal cancer. Oncol Lett 25:192. https:\/\/doi.org\/10.3892\/ol.2023.13778","journal-title":"Oncol Lett"},{"key":"4208_CR35","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1126\/science.aag0299","volume":"354","author":"LB Alexandrov","year":"2016","unstructured":"Alexandrov LB, Ju YS, Haase K, Loo PV, Martinocorena I, Nik-Zainai S et al (2016) Mutational signatures associated with tobacco smoking in human cancer. Science 354:618\u2013622. https:\/\/doi.org\/10.1126\/science.aag0299","journal-title":"Science"},{"key":"4208_CR36","doi-asserted-by":"publisher","unstructured":"Olivier M, Hollstein M, Hainaut P (2010) TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb Perspect Biol 2:a001008. https:\/\/doi.org\/10.1101\/cshperspect.a001008","DOI":"10.1101\/cshperspect.a001008"},{"key":"4208_CR37","doi-asserted-by":"publisher","first-page":"1209243","DOI":"10.3389\/fcell.2023.1209243","volume":"11","author":"S Mo","year":"2023","unstructured":"Mo S, Cai Z, Kuai W, Li X, Chen Y (2023) Universal cut off for tumor mutation burden in predicting the efficacy of anti-PD-(L)1 therapy for advanced cancers. Front Cell Dev Biol 11:1209243. https:\/\/doi.org\/10.3389\/fcell.2023.1209243","journal-title":"Front Cell Dev Biol"},{"key":"4208_CR38","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1038\/ng.3399","volume":"47","author":"F Le Loarer","year":"2015","unstructured":"Le Loarer F, Watson S, Pierron G, de Montpreville VT, Ballet S, Firmin N et al (2015) SMARCA4 inactivation defines a group of undifferentiated thoracic malignancies transcriptionally related to BAF-deficient sarcomas. Nat Genet 47:1200\u20131205. https:\/\/doi.org\/10.1038\/ng.3399","journal-title":"Nat Genet"},{"key":"4208_CR39","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1038\/modpath.2017.61","volume":"30","author":"JL Sauter","year":"2017","unstructured":"Sauter JL, Graham RP, Larsen BT, Jenkins SM, Roden AC, Boland JM (2017) SMARCA4 deficient thoracic sarcoma: a distinctive clinicopathological entity with undifferentiated rhabdoid morphology and aggressive behavior. Mod Pathol 30:1442\u20131432. https:\/\/doi.org\/10.1038\/modpath.2017.61","journal-title":"Mod Pathol"},{"key":"4208_CR40","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1038\/modpath.2017.11","volume":"30","author":"A Yoshida","year":"2017","unstructured":"Yoshida A, Kobayashi E, Kubo T, Kodaira M, Motoi T, Motoi N et al (2017) Clinicopathological and molecular characterization of SMARCA4-deficient thoracic sarcomas with comparison to potentially related entities. Mod Pathol 30:797\u2013809. https:\/\/doi.org\/10.1038\/modpath.2017.11","journal-title":"Mod Pathol"},{"key":"4208_CR41","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1097\/PAS.120000000001188","volume":"43","author":"R Perret","year":"2019","unstructured":"Perret R, Chalabreysse L, Watson S, Serre I, Garcia S, Forest F et al (2019) SMARCA4-deficient thoracic sarcomas. Clinicopathologic study of 30 cases with an emphasis on their nosology and differential diagnosis. Am J Surg Pathol 43:455\u2013465. https:\/\/doi.org\/10.1097\/PAS.120000000001188","journal-title":"Am J Surg Pathol"},{"key":"4208_CR42","unstructured":"Yoshida A, Boland JM, Le Loarer F, Jain D, Rekhtman N (2021) Thoracic SMARCA4-deficient undifferentiated tumour. In: WHO Classification of Tumours Editorial Board, eds. WHO Classification of Thoracic Tumours 5th edition. Lyons, France: International Agency for research on Cancer; :111\u20134."},{"key":"4208_CR43","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1097\/PAS.0000000000000173","volume":"38","author":"A Agaimy","year":"2014","unstructured":"Agaimy A, Rau TT, Hartmann A, Stoehr R (2014) SMARCB1 (INI1)-negative rhabdpoid carcinomas of the gastrointestinal tract. Clinicopathologic and molecular study of a highly aggressive variant with literature review. Am J Surg Pathol 38:910\u2013920. https:\/\/doi.org\/10.1097\/PAS.0000000000000173","journal-title":"Am J Surg Pathol"},{"key":"4208_CR44","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1097\/PAS00000000000000554","volume":"40","author":"A Agaimy","year":"2014","unstructured":"Agaimy A, Daun O, Markl B, Lichtmannegger I, Michal M, Hartmann A (2014) SWI\/SNF complex-deficient undifferentiated\/rhabdoid carcinomas of the gastrointestinal tract. A series of 13 cases highlighting mutually exclusive loss of SMARCA4 and SMARCA2 and frequent co-inactivation of SMARCB1 and SMARCA2. Am J Surg Pathol 40:544\u2013553. https:\/\/doi.org\/10.1097\/PAS00000000000000554","journal-title":"Am J Surg Pathol"},{"key":"4208_CR45","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1111\/his.14096","volume":"77","author":"B Tessier-Cloutier","year":"2020","unstructured":"Tessier-Cloutier B, Schaeffer DF, Bacani J, Marginean CE, Kalloger S, Kobel M et al (2020) Loss of Switch\/sucrose non-fermenting complex protein expression in undifferentiated gastrointestinal and pancreatic carcinomas. Histopathology 77:46\u201354. https:\/\/doi.org\/10.1111\/his.14096","journal-title":"Histopathology"},{"key":"4208_CR46","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1097\/PAS.0000000000001836","volume":"46","author":"B Chang","year":"2022","unstructured":"Chang B, Sheng W, Wang L, Zhu X, Tan C, Ni S et al (2022) SWI.SNF complex deficient undifferentiated carcinoma of the gastrointestinal tract. Clinicopathologic study of 30 cases with an emphasis on variable morphology, immune features, and the prognostic significance of different SMARCA4 and SMARCA2 subunit deficiencies. Am J Surg Pathol 46:889\u2013906. https:\/\/doi.org\/10.1097\/PAS.0000000000001836","journal-title":"Am J Surg Pathol"},{"key":"4208_CR47","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1097\/000125480-200007030-00007","volume":"21","author":"S Ogino","year":"2014","unstructured":"Ogino S, Ro JY, Redline RW (2014) Malignant rhabdoid tumor: a phenotype? An entity? \u2013 a controversy revisited. Adv Anat Pathol 21:394\u2013410. https:\/\/doi.org\/10.1097\/000125480-200007030-00007","journal-title":"Adv Anat Pathol"},{"key":"4208_CR48","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.1158\/1078-0432.CCR-15-1468","volume":"22","author":"EH Bell","year":"2016","unstructured":"Bell EH, Chakraborty AR, Mo X, Liu Z, Shilo K, Kirste S et al (2016) SMARCA4\/BRG1 is a novel prognostic biomarker of cisplatin based chemotherapy outcomes in resected non-small cell lung cancer. Clin Cancer Res 22:2396\u20132404. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-1468","journal-title":"Clin Cancer Res"},{"key":"4208_CR49","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1097\/PAP.00000000000000366","volume":"30","author":"A Agaimy","year":"2023","unstructured":"Agaimy A (2023) SWI\/SNF-deficient malignancies: optimal candidates for immune-oncological therapy? Adv Anat Pathol 30:211\u2013217. https:\/\/doi.org\/10.1097\/PAP.00000000000000366","journal-title":"Adv Anat Pathol"},{"key":"4208_CR50","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1093\/annonc\/mdw552","volume":"28","author":"D Morel","year":"2017","unstructured":"Morel D, Almouzni G, Soria J-C, Pastel-Vinay S (2017) Targeting chromatin defects in selected solid tumors based on oncogene addiction, synthetic lethality and epigenetic antagonism. Ann Oncol 28:254\u2013269. https:\/\/doi.org\/10.1093\/annonc\/mdw552","journal-title":"Ann Oncol"}],"container-title":["Virchows Archiv"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-025-04208-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00428-025-04208-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-025-04208-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T07:21:55Z","timestamp":1764055315000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00428-025-04208-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,7]]},"references-count":50,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["4208"],"URL":"https:\/\/doi.org\/10.1007\/s00428-025-04208-0","relation":{},"ISSN":["0945-6317","1432-2307"],"issn-type":[{"value":"0945-6317","type":"print"},{"value":"1432-2307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,7]]},"assertion":[{"value":"15 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work is compliant with the Declaration of Helsinki for medical research involving human, relevant laws, and institutional guidelines. Ethics Committee approval of the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China (reference number: ES-2023\u2013209-01 on December 5, 2023) was obtained.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}